Top

Published in:

01-11-2004 | Review Article

Long-Cycle Treatment with Oral Contraceptives

Authors: Inka Wiegratz, Prof. Dr Herbert Kuhl

Published in: Drugs | Issue 21/2004

Abstract

The conventional regimen of oral contraceptive (OC) use mimics the natural cycles by causing regular withdrawal bleeding, which can be avoided by omission of the hormone-free interval of 7 days. Consequently, long-cycle regimens with continuous administration of OCs for 3 or 6 months followed by a hormone-free interval of 7 days may reduce the frequency of menstruations and cycle-dependent complaints. Surveys have revealed that, despite a higher rate of irregular bleeding, the majority of women prefer the long-cycle regimen to the conventional OC regimen with regular bleeds every 4 weeks because it may improve quality of life.

As this regimen increases the contraceptive efficacy to a large degree, continuous treatment with OCs may prevent unintended pregnancies in women who miss a pill or are concomitantly treated with drugs that are able to impair the efficacy of OCs. Postponement of withdrawal bleeding may also reduce or prevent menses-associated disorders such as hypermenorrhoea and dysmenorrhoea, and have beneficial effects in patients with haemorrhagic diathesis, endometriosis, uterine leiomyoma and polycystic ovary syndrome. Continuous use of OCs prevents the cyclic fluctuations of serum levels of ethinylestradiol and progestogen and, hence, the cyclic variations of metabolic serum parameters.

Although the long-cycle regimen is initially associated with an elevated rate of irregular bleeding, the total number of bleeding days that require sanitary product protection is lower than during conventional OC treatment. Many physicians tend to prescribe extended OC cycles for postponement of menstruation or reduction of frequency of regular bleeding.

This review summarises and examines the available data on OC long-cycle regimens. The data suggest that the rate of treatment-related side effects with OCs according to the long-cycle regimen is similar to that of conventional OC regimens. However, clinical trials are necessary to assess the impact of long-term OC long cycles on safety, particularly the risk of cancer and cardiovascular disease, and fertility after discontinuation of treatment.

Wilbush J. La menopausie: the birth of a syndrome. Maturitas 1979; 1: 145–51PubMedCrossRef

Thomas SL, Ellertson C. Nuisance or natural and healthy: should monthly menstruation be optional for women? Lancet 2000; 355: 922–4PubMedCrossRef

Sulak P, Scow RD, Preece C, et al. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 2000; 95: 261–6PubMedCrossRef

Shakespeare J, Neve E, Hodder E. Is norethisterone a lifestyle drug? Results of database analysis. BMJ 2000; 320: 291PubMedCrossRef

den Tonkelaar I, Oddens BJ. Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status, oral contraceptive use, and hormone replacement therapy use. Contraception 1999; 59: 357–62CrossRef

Rutter W, Knight C, Vizzard J, et al. Women’s attitude to withdrawal bleeding and their knowledge and beliefs about the oral contraceptive pills. Med J Aust 1988; 149: 417–9PubMed

Glasier AF, Smith KB, van der Spuy ZM, et al. Amenorrhea associated with contraception: an international study on acceptability. Contraception 2003; 67: 1–8PubMedCrossRef

Wiegratz I, Hommel HH, Zimmermann T, et al. Attitudes of German women and gynecologists towards long-cycle treatment with oral contraceptives. Contraception 2004; 69: 37–42PubMedCrossRef

Sulak PJ, Kuehl TJ, Ortiz M, et al. Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet Gynecol 2002; 186: 1142–9PubMedCrossRef

10.

Schwartz JL, Creinin MD, Pymar HC. The trimonthly combination oral contraceptive regimen: is it cost effective? Contraception 1999; 60: 263–7PubMedCrossRef

11.

Miller L, Notter KM. Menstrual reduction with extended use of combination oral contraceptive pills: randomized controlled trial. Obstet Gynecol 2001; 98: 771–8PubMedCrossRef

12.

Braunstein JB, Hausfeld J, Hausfeld J, et al. Economics of reducing menstruation with trimonthly-cycle oral contraceptive therapy: comparison with standard-cycle regimens. Obstet Gynecol 2003; 102: 699–708PubMedCrossRef

13.

Cote I, Jacobs P, Cumming D. Work loss associated with increased menstrual loss in the United States. Obstet Gynecol 2002; 100: 683–7PubMedCrossRef

14.

Rosenberg M, Waugh MS. Causes and consequences of oral contraceptive noncompliance. Am J Obstet Gynecol 1999; 180: S276–9CrossRef

15.

Guillebaud J. The forgotten pill: and the paramount importance of the pill-free week. Br J Fam Plann 1987; 12 Suppl.: S35–43

16.

Wang E, Shi S, Cekan SZ, et al. Hormonal consequences of ‘missing the pill’. Contraception 1982; 26: 545–66PubMedCrossRef

17.

Fraser IS, Jansen RPS. Why do inadvertent pregnancies occur in oral contraceptive users? Effectiveness of oral contraceptive regimens and interfering factors. Contraception 1983; 27: 531–51PubMedCrossRef

18.

Kuhl H, Gahn G, Romberg G, et al. A randomized cross-over comparison of two low-dose oral contraceptives upon hormonal and metabolic parameters. 1: effects on sexual hormone levels. Contraception 1985; 31: 583–93

19.

Molloy BG, Coulson KA, Lee JM, et al. ‘Missed pill’ conception: fact or fiction? BMJ 1985; 290: 1474–5PubMedCrossRef

20.

Jung-Hoffmann C, Heidt F, Kuhl H. Effect of two oral contraceptives containing 30 μg ethinylestradiol and 75 μg gestodene or 150 μg desogestrel upon various hormonal parameters. Contraception 1998; 38: 593–603CrossRef

21.

Killick SR, Bancroft K, Oelbaum S, et al. Extending the duration of the pill-free interval during combined oral contraception. Adv Contracept 1990; 6: 33–40PubMedCrossRef

22.

Aden U, Jung-Hoffmann C, Kuhl H. A randomized cross-over study on various hormonal parameters of two triphasic oral contraceptives. Contraception 1998; 58: 75–81PubMedCrossRef

23.

Hamilton CJCM, Hoogland HJ. Longitudinal ultrasonographic study of the ovarian suppressive activity of a low-dose triphasic oral contraceptive during correct and incorrect pill intake. Am J Obstet Gynecol 1989; 161: 1159–62PubMed

24.

Killick SR. Ovarian follicles during oral contraceptive cycles: their potential for ovulation. Fertil Steril 1989; 52: 580–2PubMed

25.

Hoogland HJ, Skouby SO. Ultrasound evaluation of ovarian activity under oral contraceptives. Contraception 1993; 47: 583–90PubMedCrossRef

26.

Spona J, Elstein M, Feichtinger W, et al. Shorter pill-free interval in combined oral contraceptives decreases follicular development. Contraception 1996; 54: 71–7PubMedCrossRef

27.

Sullivan H, Furniss H, Spona J, et al. Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 μg) and ethinyl estradiol (15 μg) on ovarian activity. Fertil Steril 1999; 72: 115–20PubMedCrossRef

28.

Anderson FD, Hait H. A multicenter, randomized study of an extended cycle oral contraceptive: the Seasonale-301 Study Group. Contraception 2003; 68: 89–96PubMedCrossRef

29.

Loudon NB, Foxwell M, Potts DM, et al. Acceptability of an oral contraceptive that reduces the frequency of menstruation: the tri-cyclic pill regimen. BMJ 1977; 2: 487–90PubMedCrossRef

30.

Hamerlynck JVTH, Vollebregt JA, Doornebos CM, et al. Postponement of withdrawal bleeding in women using low-dose combined oral contraceptives. Contraception 1987; 35: 199–205PubMedCrossRef

31.

de Voogt WS. Postponement of withdrawal bleeding with a monophasic oral contraceptive containing desogestrel and ethinylestradiol. Contraception 1991; 44: 107–12CrossRef

32.

Kornaat H, Geerdink MH, Klitsie JW. The acceptance of a 7-week cycle with a modern low-dose oral contraceptive (Minulet). Contraception 1992; 45: 121–7CrossRef

33.

Cachrimanidou A-C, Hellberg D, Nilsson S, et al. Long-interval treatment regimen with a desogestrel-containing oral contraceptive. Contraception 1993; 48: 205–16PubMedCrossRef

34.

Cachrimanidou A-C, Hellberg D, Nilsson S, et al. Hemostasis profile and lipid metabolism with long interval use of a desogestrel-containing oral contraceptive. Contraception 1994; 50: 153–65PubMedCrossRef

35.

Kovacs GT, Rusden J, Evans A. A trimonthly regimen for oral contraceptives. Br J Fam Plann 1994; 19: 274–5

36.

Coutinho EM, O’Dwyer E, Barbosa IC, et al. Comparative study on intermittent versus continuous use of a contraceptive pill administered by vaginal route. Contraception 1995; 51: 355–8PubMedCrossRef

37.

Ruchhoft E, Elkind-Hirsch KE, Malinak R. Pituitary function is altered during the same cycle in women with polycystic ovary syndrome treated with continuous or cyclic oral contraceptives or a gonadotropin-releasing hormone agonist. Fertil Steril 1996; 66: 54–60PubMed

38.

Sulak PJ, Cressman BE, Waldrop E, et al. Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptoms. Obstet Gynecol 1997; 89: 179–83PubMedCrossRef

39.

Vercellini P, De Giorgi O, Mosconi P, et al. Cyproterone acetate versus a continuous monophasic oral contraceptive in the treatment of recurrent pelvic pain after conservative surgery for symptomatic endometriosis. Fertil Steril 2002; 77: 52–61PubMedCrossRef

40.

Kwiecin M, Edelman A, Nichols MD, et al. Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: a randomized trial. Contraception 2003; 67: 9–13CrossRef

41.

Miller L, Hughes JP. Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial. Obstet Gynecol 2003; 101: 653–61PubMedCrossRef

42.

Back DJ, Breckenridge AM, Crawford F, et al. Interindividual variation and drug interactions with hormonal steroid contraceptives. Drugs 1981; 21: 46–61PubMedCrossRef

43.

D’Arcy PF. Drug interactions with oral contraceptives. Drug Intell Clin Pharm 1986; 20: 353–62PubMed

44.

Back DJ, Grimmer SFM, Orme MLE, et al. Evaluation of committee on safety of medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics. Br J Clin Pharmacol 1988; 25: 527–32PubMedCrossRef

45.

Back DJ, Orme MLE. Pharmacokinetic drag interactions with oral contraceptives. Clin Pharmacokinet 1990; 18: 472–84PubMedCrossRef

46.

Diamond MP, Greene JW, Thompson JM, et al. Interactions of anticonvulsants and oral contraceptives in epileptic adolescents. Contraception 1985; 31: 623–32PubMedCrossRef

47.

Jung-Hoffmann C, Kuhl H. Pharmacokinetics and pharmacodynamics of oral contraceptive steroids: factors influencing steroid metabolism. Am J Obstet Gynecol 1990; 163: 2183–97

48.

Szoka PR, Edgren RA. Drag interactions with oral contraceptives: compilation and analysis of an adverse experience report database. Fertil Steril 1988; 49 (5 Suppl. 2): 31–8

49.

Park BK, Kitteringham NR, Pirmohamed M, et al. Relevance of induction of human drag-metabolizing enzymes: pharmacological and toxicological implications. Br J Pharmacol 1996; 41: 477–91

50.

Birkhäuser M, Braendle W, Breckwoldt M, et al. 24th Workshop of the ‘Zürcher Gesprächskreis’ May 2000: recommendations on oral contraception. Frauenarzt 2000; 41: 1053–8

51.

Zeitoun K, Takayama K, Sasano H, et al. Deficient 17β-hydrxysteroid dehydrogenase type 2 expression in endometriosis: failure to metablize 17β-estradiol. J Clin Endocrinol Metab 1998; 83: 4474–80PubMedCrossRef

52.

Brosens IA, Pijnenborg R. Comparative study of the estrogenic effect of ethinylestradiol and mestranol on the endometrium. Contraception 1976; 14: 679–85PubMedCrossRef

53.

Parazzini F, Ferraroni M, Bocciolone L, et al. Contraceptive methods and risk of pelvic endometriosis. Contraception 1994; 49: 47–55PubMedCrossRef

54.

Pickersgill A. GnRH agonists and add-back therapy: is there a perfect combination? Br J Obstet Gynaecol 1998; 105: 475–85PubMedCrossRef

55.

Marshall LM, Spiegelman D, Goldman MB, et al. A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata. Fertil Steril 1998; 70: 432–9PubMedCrossRef

56.

Friedman AJ, Thomas PP. Does low-dose combination oral contraceptive use affect uterine size or menstrual flow in premenopausal women with leiomyomas? Obstet Gynecol 1995; 85: 631–5PubMedCrossRef

57.

Kitawaki J, Kado N, Ishihara H, et al. Endometriosis: the pathophysiology as an estrogen-dependent disease. J Steroid Biochem Mol Biol 2003; 83: 149–55CrossRef

58.

Diamanti-Kandarakis E, Baillargeon JP, Iuorno MJ, et al. Controversies in endocrinology: a modem medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. J Clin Endocrinol Metab 2003; 88: 1927–32PubMedCrossRef

59.

Legro RS. Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev 2003; 24: 302–12PubMedCrossRef

60.

Rizk DEE, Kumar RM. Congenital afibrinogenemia: treatment of excessive menstrual bleeding with continuous oral contraceptive. Am J Hematol 1996; 52: 237–8PubMedCrossRef

61.

Milman N, Clausen J, Byg KE. Iron status in 268 Danish women aged 18–30 years: influence of menstruation, contraceptive method, and iron supplementation. Ann Hematol 1998; 77: 13–9PubMedCrossRef

62.

Chuong CJ, Brenner PF. Management of abnormal uterine bleeding. Am J Obstet Gynecol 1996; 175: 787–92PubMedCrossRef

63.

Sveindottir H, Bäckström T. Prevalence of menstrual cycle symptom cyclicity and premenstrual dysphoric disorder in a random sample of women using and not using oral contraceptives. Acta Obstet Gynecol Scand 2000; 79: 405–13PubMedCrossRef

64.

Oinonen KA, Mazmanian D. To what extent do oral contraceptives influence mood and affect? J Affect Disord 2002; 70: 229–40PubMedCrossRef

65.

Mattson RH, Rebar RW. Contraceptive methods for women with neurologic disorders. Am J Obstet Gynecol 1993; 168: 2027–32PubMed

66.

Dennerstein L, Morse C, Burrows G, et al. Menstrual migraine: a double-blind trial of percutaneous estradiol. Gynecol Endocrinol 1988; 2: 113–20PubMedCrossRef

67.

Lichten EM, Lichten JB, Whitty A. The confirmation of a biochemical marker for women’s hormonal migraine: the depo-estradiol challenge test. Headache 1996; 36: 367–71PubMedCrossRef

68.

Sulak PJ. Creative use of oral contraceptives in the perimenopausal patient. In: Santoro N, Goldstein SR, editors. Textbook of perimenopausal gynecology. New York: Parthenon, 2003: 99–107

69.

Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347: 1713–27CrossRef

70.

Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med 2002; 346: 2025–32PubMedCrossRef

71.

Stanford JL, Brinton LA, Berman ML, et al. Oral contraceptives and endometrial cancer: do other risk factors modify the association? Int J Cancer 1993; 54: 243–8PubMedCrossRef

72.

Weiderpass E, Adami HO, Baron JA, et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999; 91: 1131–7PubMedCrossRef

73.

Farrow A, Hull MGR, Northstone K, et al. Prolonged use of oral contraception before a planned pregnancy is associated with a decreased risk of delayed conception. Hum Reprod 2002; 10: 2754–61CrossRef

74.

The European Medicines Agency (Committee for Medicinal Products for Human Use [CHMP]). Note for guidance on clinical investigation of steroid contraceptives in women [draft]. London: EMEA, 2004 Jun 23

75.

Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of strogen plus progestin on breast cancer and mammography in healthy postmenopausal women. JAMA 2003; 289: 3243–53PubMedCrossRef

76.

The Women’s Health Initiative Steering Committee. Effect of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 2004; 291: 1701–12CrossRef

77.

Bush TL, Whiteman M, Flaws JA. Hormone replacement therapy and breast cancer: a qualitative review. Obstet Gynecol 2001; 98: 498–508PubMedCrossRef

78.

Hofseth LJ, Raafat AM, Osuch JR, et al. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 1999; 84: 4559–65PubMedCrossRef

79.

Cline JM, Soderqvist G, von Schoultz E, et al. Effect of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques. Am J Obstet Gynecol 1996; 174: 93–100PubMedCrossRef

80.

Suparto IH, Williams JK, Cline JM, et al. Contrasting effects of two hormone replacement therapies on the cardiovascular and mammari gland outcomes in surgically postmenopausal monkeys. Am J Obstet Gynecol 2003; 188: 1132–40PubMedCrossRef

81.

Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419–27CrossRef

82.

Brinton LA, Vessey MP, Flavel R, et al. Risk factors for benign breast disease. Am J Epidemiol 1981; 113: 203–14PubMed

83.

Bloemenkamp KWM, Rosendaal FR, Biiller HR, et al. Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. Arch Intern Med 1999; 159: 65–70PubMedCrossRef

84.

Bloemenkamp KWM, Rosendaal FR, Heimerhorst FM, et al. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Intern Med 2000; 160: 49–52PubMedCrossRef

85.

Rosendaal FR. Thrombosis in the young: epidemiology and risk factors. A focus on venous thrombosis. Thrombos Haemost 1997; 78: 1–6

86.

Duffy TJ, Ray R. Oral contraceptive use: prospective follow-up of women with suspected glucose intolerance. Contraception 1984; 40: 197–208CrossRef

87.

Jung-Hoffmann C, Kuhl H. Intra- and interindividual variations in contraceptive steroid levels during 12 treatment cycles: no relation to irregular bleedings. Contraception 1990; 42: 423–8PubMedCrossRef

88.

Kuhl H, Jung-Hoffmann C, Storch A, et al. New aspects on the mechanism of action of contraceptive steroids: recent pharmacokinetic studies of low dose formulations. Adv Contraception 1991; 7 Suppl. 3: 149–63

89.

Kuhl H, Jung-Hoffmann C, Heidt F. Serum levels of 3-ketodesogestrel and SHBG during 12 cycles of treatment with 30 μg ethinylestradiol and 150 μg desogestrel. Contraception 1988; 38: 381–90PubMedCrossRef

90.

März W, Jung-Hoffmann C, Heidt F, et al. Changes in lipid metabolism during 12 months of treatment with two oral contraceptives containing 30 μg ethinylestradiol and 75 μg gestodene or 150 μg desogestrel. Contraception 1990; 41: 245–58PubMedCrossRef

91.

Jung-Hoffmann C, Kuhl H. Interaction with the pharmacokinetics of ethinylestradiol and progestins contained in oral contraceptives. Contraception 1989; 40: 299–312PubMedCrossRef

92.

Clarke AK, Miller SJ. The debate regarding continuous use of oral contraceptives. Ann Pharmacotherapy 2001; 35: 1480–4CrossRef

Title: Long-Cycle Treatment with Oral Contraceptives
Authors: Inka Wiegratz
Prof. Dr Herbert Kuhl
Publication date: 01-11-2004
Publisher: Springer International Publishing
Published in: Drugs / Issue 21/2004
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200464210-00006

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Long-Cycle Treatment with Oral Contraceptives

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 21/2004

Therapeutic Potential of Oral Antiproliferative Agents in the Prevention of Coronary Restenosis

Trospium Chloride in the Management of Overactive Bladder

Gefitinib

Management of Acute and Chronic Gouty Arthritis

Progesterone Treatment to Prevent Preterm Birth

Aspirin-Induced Asthma